To evaluate the role of USP7 on cancer cell growth under conditions where cancer cells are interacting with other TME components, we assessed the response of 3D tumour spheroids composed of cancer cells, fibroblasts and CD3/CD28‐activated immune cells to treatment with the USP7 inhibitor. The gene discussed is CD28; the disease is neoplasm.